Remed리메드

Remed's revenue and profit have held up on a trailing basis, but the share price has fallen sharply over the past year.

Remed, a KOSDAQ-listed maker of non-invasive magnetic and electrical stimulation devices, reported trailing twelve-month revenue of ₩27.1B and net income of ₩2.1B to H1 2026, with ₩9.0B in cash against ₩1.5B in borrowings. The shares closed at ₩2,245 on 2026-10-23, down 35.5% over one year and near the lower half of their 52-week range.

What stands out

• Trailing operating margin is 7.2%, well above the 3.0% reported for 2025, though 2025 revenue fell 4.1% year on year.
• 2024 net income of ₩7.2B was far above operating income of ₩1.1B, so that year's profit was not driven by core operations alone; the data does not explain the gap.
• Recent filings include several 5%+ holding reports, a convertible bond issue decision with an amendment, and a share cancellation decision.
• News reports say Pointers PE and LF Investment each plan to invest ₩15B in Remed, with LF to become the No. 2 shareholder upon convertible bond conversion.
• Against peers, the trailing P/E of 33.2 sits above Kctech (21.5) and Classys (13.2) but below TSE (27.2)... and well below Park Systems (71.9).

What to watch

• Whether the planned ₩15B investments and convertible bond conversion complete, and how they affect the share count and shareholder structure.
• The full-year 2026 results, since the data only runs to H1 2026 and the trailing figures may shift.
• The DCF fair value range in the data is ₩461 to ₩1,282 with a base of ₩753, well below the current price; the data does not explain the gap, and the model is not a forecast.